Regulation - Pricing, Pfizer

Filter

Current filters:

PricingPfizer

Popular Filters

Report: Tarceva and Iressa favored by European oncologists for NSCLC

Report: Tarceva and Iressa favored by European oncologists for NSCLC

04-11-2013

Oncologists across the top five European countries are prescribing Roche's Tarceva or AstraZeneca's Iressa…

AstraZenecaEuropeIressaOncologyPfizerPharmaceuticalPricingRegulationRocheTarcevaXalkori

NICE says Xalkori is not cost effective in ALK-positive NSCLC

20-08-2013

US pharma behemoth Pfizer (NYSE: PFE) has today (August 16) expressed concern and disappointment that…

EuropeOncologyPfizerPharmaceuticalPricingRegulationXalkori

Negative NICE news for Pfizer leukemia drug

16-07-2013

There was disappointment for global drugs behemoth Pfizer (NYSE: OFE) when the UK drugs watchdog the…

BosulifEuropeOncologyPfizerPharmaceuticalPricingRegulation

Germany's IQWiG finds considerable added benefit for Bristol-Myers/Pfizer's Eliquis

05-04-2013

In an early benefit assessment under the German Act on the Reform of the Market for Medicinal Products…

Bristol-Myers SquibbCardio-vascularEliquisEuropePfizerPharmaceuticalPricingRegulation

NICE denies NHS use of Pfizer's Inlyta for patients with terminal kidney cancer

28-03-2013

In a second disappointment from the agency this week, US drugs behemoth Pfizer (NYSE: PFE) Ltd expressed…

EuropeInlytaOncologyPfizerPharmaceuticalPricingRegulation

German drugs watchdog finds "hint of considerable added benefit" for Pfizer's Inlyta

09-01-2013

The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined the added benefit…

BayerEuropeInlytaNexavarOncologyPfizerPharmaceuticalPricingRegulation

Australia to add Pfizer's Lyrica to PBS list; call for antibiotic research incentives

18-11-2012

Australia's Health Minister Tanya Plibersek on Friday announced the government's decision to subsidize…

Asia-PacificLyricaPfizerPharmaceuticalPricingRegulationResearch

Germany's IQWiG finds some benefit for Pfizer orphan drug Vyndaqel

11-04-2012

The German Institute for Quality and Efficiency in Health Care (IQWiG) has assessed Vyndaqel (tafamidis),…

EuropePfizerPharmaceuticalPricingRare diseasesRegulationVyndaqel

German IQWiG finds mixed added benefits for Eliquis

02-04-2012

In an early benefit assessment under the Act on the Reform of the Market for Medicinal Products (AMNOG),…

Bristol-Myers SquibbCardio-vascularEliquisEuropePfizerPharmaceuticalPricingRegulation

Parexel

Parexel

Back to top